Bright Minds Biosciences is a biotechnology company. Co. is creating chemical entities as targeted therapeutic agents for treatment of disorders where a serotonin (5-HT) receptor (either 5-HT2A, 5-HT2C or 5-HT2A/C) driven mechanism is the underlying pathology. These targeted neurocircuit disorders include neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders. Examples of these diseases include 5-HT2C disorders like pediatric epilepsies, Alzheimer's disease psychosis and dementia, 5-HT2A receptor disorders like depression and post-traumatic stress disorder, and 5-HT2A/C neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. The DRUG average annual return since 2021 is shown above.
The Average Annual Return on the DRUG average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DRUG average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DRUG average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|